Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags, Joanne T.M. Tan, Keyvan K. Galougahi, Andreas Schaefer, Steven G. Wise, Andrew Murphy, Ziad A. Ali, Christina A. Bursill

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

Original languageEnglish
Pages (from-to)200-209
Number of pages10
JournalJACC: Basic to Translational Science
Volume3
Issue number2
DOIs
StatePublished - Apr 2018
Externally publishedYes

Keywords

  • apolipoprotein A-I
  • endothelialization
  • neointimal hyperplasia
  • platelet activation
  • stent biocompatibility

Fingerprint

Dive into the research topics of 'Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype'. Together they form a unique fingerprint.

Cite this